Statistics on the Marshall Protocol

The primary function of the Marshall Protocol (MP) study site is to learn how the MP affects and improves the health of patients with a variety of inflammatory conditions. As of February 2009, there are about 1,000 patients who regularly post in their progress reports on the MP study site. Autoimmunity Research Foundation is currently in the process of partnering with a hospital which has the resources necessary to manage a large-scale cohort study of the MP.

One of the observations seen in the online progress reports–and confirmed in independent reports coming from MP physicians whose patients do not post on the study site–is that nearly everyone on the MP experiences immunopathology. Some estimate this number to be as high as 99%; others are more conservative and say it is 95%. Immunopathology is the calculated rise and fall in symptoms and is a sign that bacteria are being killed. Immunopathology seems to be independent of the diagnosis given to the disease.

The best data collected thus far is from a 2008 survey of MP patients with autoimmune diseases, the methodology of which is described here. That data was presented by Capt. Tom Perez, MPH, at the 2008 International Congress on Autoimmunity.

ARF is currently in the process of partnering with a hospital which has the resources necessary to manage a large-scale cohort study of the MP.